Related Experiment Video
Updated: Jun 19, 2026
08:04
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
Caffeine-potentiated chemotherapy for metastatic osteosarcoma
Hiroaki Kimura1, Hiroyuki Tsuchiya, Toshiharu Shirai
1Department of Orthopaedic Surgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Ishikawa, Japan.
Summary
Caffeine-potentiated chemotherapy improved survival for osteosarcoma patients with lung metastases. Early detection and solitary nodules significantly improved patient prognoses, offering new hope for this challenging cancer.
Area of Science:
- Oncology
- Pharmacology
- Cancer Research
Background:
- Metastatic osteosarcoma has a poor prognosis despite current chemotherapy.
- Caffeine enhances anticancer drug efficacy, forming the basis for novel treatment strategies.
- This study investigates caffeine-potentiated chemotherapy in osteosarcoma with pulmonary metastases.
Purpose of the Study:
- To evaluate the efficacy of caffeine-potentiated chemotherapy in patients with osteosarcoma and pulmonary metastases.
- To identify prognostic factors influencing survival in this patient cohort.
Main Methods:
- Retrospective analysis of 41 patients treated between 1990 and 2006.
- Assessment of overall survival and prognostic variables.
- Focus on caffeine-potentiated chemotherapy regimens.
Main Results:
- Overall survival rates at 2 and 5 years were 38% and 28%, respectively.
- Key prognostic factors identified include primary tumor site, histological response, and pulmonary metastasis characteristics.
- Solitary pulmonary nodules and metastasis detected post-treatment correlated with better prognoses.
Conclusions:
- Caffeine-potentiated chemotherapy demonstrated a survival benefit for osteosarcoma patients with pulmonary metastases.
- Early identification of solitary pulmonary nodules and post-treatment metastasis detection are favorable prognostic indicators.
Related Concept Videos
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...